Modified Poloxamer 407 and Hyaluronic Acid Thermosensitive Hydrogel-encapsulated Keratinocyte Growth Factor 2 Improves Knee Osteoarthritis in Rats

Abstract Objectives The purpose of this study was to examine the daily consumption of tart cherry juice in comparison to a placebo juice on symptoms associated with knee osteoarthritis in both men and woman, age 45–79 years old, for a treatment period of 120 days. Methods In a randomized, double-blind control trial, a total of 66 adults with self-reported symptomatic knee OA, were randomized to either consume a 16 oz of tart cherry juice (TCJ) or a placebo juice daily for 4 months. Pain, mobility, plasma biomarkers of cartilage metabolism were evaluated at baseline, 2 months and 4 months. Pain, stiffness, and impact on quality of life were assessed using Self-administered Modified Short Form McGill Pain Questionnaire, while flexibility of the afflicted joint(s) was assessed via range of motion assessment (ROM). Plasma biomarkers related to cartilage metabolism such as glycoprotein 39 (YKL-40), hyaluronic acid, insulin-like growth factor(IGF)-1, and insulin-like growth factor binding protein (IGFBP-3) were determined. Results A total of 57 participants completed the study with an attrition rate of 9%. Pain and impact on quality of life decreased significantly at mid-point in the TCJ group, but these improvements were not maintained at the final time point. At midpoint, right knee ROM increased significantly in the TCJ at mid-point, but did not maintain significant at the end of the treatment period. Knee extension and knee flexion also improved significantly in the TCJ group from baseline to midpoint, while there was no significant change in the placebo group. The TCJ group had an overall significant decrease in plasma YKL-40, a marker of cartilage destruction, while no changes were observed in the placebo group. A significant decrease in the plasma IGF-1 and a non-significant up trend in IGFBP-3 were observed in the placebo group, while in the TCJ group no changes in IGF-1 and a non-significant decrease in IGFBP-3 was observed. There were no changes in the hyaluronic acid in the TCJ group during the study duration, but a non-significant up trending was noticed in the placebo group. Conclusions The findings of the study suggest that daily consumption of tart cherry juice results in improvement in mobility, relief of pain-related symptoms and quality of life, and selective markers of cartilage health. Funding Sources Cherry Marketing Institute.

Download Full-text

AB0976 Efficacy of intra-articular injection of prp- drived growth factor (PRP WITHOUT PLATELET AND WBC) versus hyaluronic acid on pain and function of patients with knee osteoarthritis: a single-blinded randomised clinical trial

10.1136/annrheumdis-2018-eular.3701 ◽

2018 ◽

Author(s):

S.A. Raeissadat ◽

A. gharooee ahangar ◽

S.M. Rayegani

Keyword(s):

Clinical Trial ◽

Hyaluronic Acid ◽

Growth Factor ◽

Knee Osteoarthritis ◽

Randomised Clinical Trial ◽

And Function

Download Full-text

KGF-2 and FGF-21 poloxamer 407 hydrogel coordinates inflammation and proliferation homeostasis to enhance wound repair of scalded skin in diabetic rats

BMJ Open Diabetes Research & Care ◽

10.1136/bmjdrc-2019-001009 ◽

2020 ◽

Vol 8 (1) ◽

pp. e001009 ◽

Cited By ~ 2

Author(s):

Xuanxin Yang ◽

Rongshuai Yang ◽

Min Chen ◽

Qingde Zhou ◽

Yingying Zheng ◽

...

Keyword(s):

Type 2 Diabetes ◽

Wound Healing ◽

Growth Factor ◽

Granulation Tissue ◽

Inflammatory Responses ◽

Poloxamer 407 ◽

Thermosensitive Hydrogel ◽

Gk Rats ◽

Wound Model

ObjectiveThe present study focused on the development of a poloxamer 407 thermosensitive hydrogel loaded with keratinocyte growth factor-2 (KGF-2) and fibroblast growth factor-21 (FGF-21) as a therapeutic biomaterial in a scald-wound model of type-2 diabetes in Goto-Kakizaki (GK) rats.Research design and methodsIn this study, a poloxamer 407 thermosensitive hydrogel loaded with KGF-2 and/or FGF-21 was prepared and its physical and biological properties were characterized. The repairing effects of this hydrogel were investigated in a scald-wound model of type-2 diabetes in GK rats. The wound healing rate, epithelialization, and formation of granulation tissue were examined, and biomarkers reflecting regulation of proliferation and inflammation were quantified by immunostaining and Western blotting. T tests and analyses of variance were used for statistical analysis via Graphpad Prism V.6.0.ResultsA 17.0% (w/w) poloxamer 407 combined with 1.0% (w/w) glycerol exhibited controlled release characteristics and a three-dimensional structure. A KGF-2/FGF-21 poloxamer hydrogel promoted cellular migration without apoptosis. This KGF-2/FGF-21 poloxamer hydrogel also accelerated wound healing of scalded skin in GK rats better than that of a KGF-2 or FGF-21 hydrogel alone due to accelerated epithelialization, formation of granulation tissue, collagen synthesis, and angiogenesis via inhibition of inflammatory responses and increased expression of alpha-smooth muscle actin (α-SMA), collagen III, pan-keratin, transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), and CD31.ConclusionsA KGF-2/FGF-21 poloxamer hydrogel accelerated wound healing of scalded skin in GK rats, which was attributed to a synergistic effect of KGF-2-mediated cellular proliferation and FGF-21-mediated inhibition of inflammatory responses. Taken together, our findings provide a novel and potentially important insight into improving wound healing in patients with diabetic ulcers.

Download Full-text

THU0422 COMPARISON OF PRP DERIVED GROWTH FACTOR (PRGF) VERSUS HYALURONIC ACID (HA) IN MILD TO MODERATE KNEE OSTEOARTHRITIS; A SINGLE BLIND ONE YEAR RANDOMIZED CLINICAL TRIAL STUDY

10.1136/annrheumdis-2019-eular.2294 ◽

2019 ◽

Author(s):

Seyed Ahmad Raeissadat ◽

Azadeh Gharooee Ahangar ◽

Seyed Mansoor Rayegani ◽

Pegah Yavari

Keyword(s):

Clinical Trial ◽

Hyaluronic Acid ◽

Growth Factor ◽

Knee Osteoarthritis ◽

Randomized Clinical Trial ◽

One Year ◽

Single Blind

Download Full-text

Efficacy of Intra-articular Injection of a Newly Developed Plasma Rich in Growth Factor (PRGF) Versus Hyaluronic Acid on Pain and Function of Patients with Knee Osteoarthritis: A Single-Blinded Randomized Clinical Trial

Clinical Medicine Insights Arthritis and Musculoskeletal Disorders ◽

10.1177/1179544117733452 ◽

2017 ◽

Vol 10 ◽

pp. 117954411773345 ◽

Cited By ~ 17

Author(s):

Seyed Ahmad Raeissadat ◽

Seyed Mansoor Rayegani ◽

Azadeh Gharooee Ahangar ◽

Porya Hassan Abadi ◽

Parviz Mojgani ◽

...

Keyword(s):

Clinical Trial ◽

Hyaluronic Acid ◽

Growth Factor ◽

Knee Osteoarthritis ◽

Randomized Clinical Trial ◽

Repeated Measures ◽

Significant Difference ◽

Within Subjects ◽

The Mean ◽

And Function

Background and objectives: Knee osteoarthritis is the most common joint disease. We aimed to compare the efficacy and safety of intra-articular injection of a newly developed plasma rich in growth factor (PRGF) versus hyaluronic acid (HA) on pain and function of patients with knee osteoarthritis. Methods: In this single-blinded randomized clinical trial, patients with symptomatic osteoarthritis of knee were assigned to receive 2 intra-articular injections of our newly developed PRGF in 3 weeks or 3 weekly injections of HA. Our primary outcome was the mean change from baseline until 2 and 6 months post intervention in scores of visual analog scale, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Lequesne index. We used analysis of variance for repeated-measures statistical test. Results: A total of 69 patients entered final analysis. The mean age of patients was 58.2 ± 7.41 years and 81.2% were women. In particular, total WOMAC index decreased from 42.9 ± 13.51 to 26.8 ± 13.45 and 24.4 ± 16.54 at 2 and 6 months in the newly developed PRGF group (within subjects P = .001), and from 38.8 ± 12.62 to 27.8 ± 11.01 and 27.4 ± 11.38 at 2 and 6 months in the HA group (within subjects P = .001), respectively (between subjects P = .631). There was no significant difference between PRGF and HA groups in patients’ satisfaction and minor complications of injection, whereas patients in HA group reported significantly lower injection-induced pain. Conclusions: In 6 months follow up, our newly developed PRGF and HA, both are effective options to decrease pain and improvement of function in patients with symptomatic mild to moderate knee osteoarthritis.

Download Full-text